ClinicalTrials.gg
CompletedNCT03449758SariPROUpdated Apr 28, 2022Results posted

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

A Phase 4 interventional study of SARILUMAB and Azathioprine in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 33 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-28.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
12th of 22
84 · median 88
Started
2018
with 1 other
Phase 4
2 of 22
none open now
Registered
17th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 12th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 4, and was the 17th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To assess the effect of sarilumab in combination with conventional synthetic Disease-Modifying Anti-Rheumatic Drug (csDMARD) and/or monotherapy on participant-reported impact of disease, using the rheumatoid arthritis impact of disease (RAID) questionnaire, in participants with moderately to severely active rheumatoid arthritis (RA) and inadequate response or intolerance to current csDMARD or tumor necrosis factor (TNF) inhibitors.

Secondary Objectives:

  • To assess the change of the RAID score from baseline (to Week 4, Week 12, and Week 24) in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors, treated with sarilumab in combination with csDMARD and/or monotherapy.
  • To assess the effect of sarilumab in combination with csDMARD and/or monotherapy on other participant-reported outcomes (global assessment of disease activity, disability, morning stiffness, fatigue, anxiety/depression, mood disorders, and physical activities) in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors.
  • To assess the efficacy of sarilumab in combination with csDMARD and/or monotherapy using disease activity score-28 for RA with erythrocyte sedimentation rate (DAS28-ESR) and clinical disease activity index in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors.
  • To assess the safety of sarilumab in combination with csDMARD and/or monotherapy in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors.
Read the detailed description

The study duration per participant was approximately 32 weeks, with up to 4-week screening, 24 weeks treatment period, and 2-4 weeks post-treatment observations.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with moderately to severely active RA to European League against Rheumatology (EULAR)/American College of Rheumatology (ACR) Criteria.
  • Participants with moderate to severe disease activity defined as a DAS28-ESR greater than (>) 3.2 at Screening.
  • Participants with inadequate response within at least the last 3 months or intolerance to current csDMARD or to at least one anti-TNF therapy (as defined by the investigator).
  • Oral (less than or equal to [\<=] 15 mg/day prednisone or equivalent) and nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 (up to the maximum recommended dose) were allowed if taken at a stable dose for at least 4 weeks prior to Baseline.
  • Permitted csDMARDs were allowed if taken at a stable dose for at least 4 weeks prior to Baseline.
  • Participants abled and given written and complied with the requirements of the study protocol.

Exclusion criteria

Exclusion criteria:

  • Less than (\<) 18 years of age.
  • Participant unable to understand and write adequately to complete the study participant related outcome assessments.
  • Exposure to sarilumab at any time prior to Baseline visit.
  • Use of intra-articular or parenteral within 4 weeks prior to Baseline.
  • Treatment with any agent within the 4 weeks of Screening.
  • Last RA treatment prior to inclusion with any anti-Janus kinase (JAK) or biologic DMARD other than anti-TNF.
  • Participants treated with anti-TNF (i.e. adalimumab, infliximab, certolizumab, golimumab, etanercept) before the screening period, which are maintained within the 4 weeks before the inclusion (i.e. the first injection of sarilumab).
  • Rheumatic disease other than RA or prior history or current inflammatory joint disease other than RA.
  • Evidence of active malignant disease, diagnosed within the previous 10 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri previously excised and cured).
  • Participant who was institutionalized due to regulatory or legal order or participant who was mentally disabled or educationally disadvantaged.
  • Pregnant or breastfeeding woman.
  • Women of not protected by highly-effective method(s) of birth control (as defined in the form and/or in a local protocol addendum/amendment) over the study period and for at least 3 months following the last dose of sarilumab, and/or who are unwilling or unable to be tested for pregnancy.
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies (or to any of the associated to sarilumab).
  • Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.
  • Stage III or IV cardiac failure according to the classification.
  • History of previous gastrointestinal perforation or diverticulitis.
  • Known active current/ recurrent infections (including but not limited to active tuberculosis [TB] or history of incompletely treated TB and atypical mycobacterial disease, and C, and herpes zoster). NOTE: in case of latent TB infection the participant might be included if a subsequent appropriate anti TB treatment is initiated since at least 3 weeks.
  • Positive hepatitis B surface antigen, and/or positive total hepatitis B core antibody, and/or positive antibody at the Screening visit.
  • Evidence of serious uncontrolled concomitant disease, including severe uncontrolled hypercholesterolemia or hypertriglyceridemia.
  • Participants with any of the following laboratory abnormalities at the Screening or Baseline visit:

    • \<8.5 grams per deciliter.
    • White blood cells \<3000/cubic millimeter (mm\^3).
    • \<2000/mm\^3
    • Absolute lymphocyte count \<500/mm\^3
    • count \<150 000 cells/mm\^3
    • \<30 milliliter per minute.
    • or Alanine aminotransaminase >1.5 x (ULN).
    • (total) >ULN, unless Gilbert's disease has been determined by genetic testing and has been documented
    • Total fasting cholesterol >3.50 gram per liter (g/L) [9.1 millimoles per liter {mmol/L}]) or triglycerides >5.00 g/L [5.6 mmol/L]).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Sarilumab

    Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.

    Drug: SARILUMAB · Drug: Azathioprine · Drug: Chloroquine · Drug: Hydroxychloroquine · Drug: Leflunomide · Drug: Methotrexate · Drug: Sulfasalazine

Interventions

  • Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous

    Also known as: SAR153191 (REGN88), Kevzara®

  • Pharmaceutical form:Tablet Route of administration: Oral

  • Pharmaceutical form:Tablet Route of administration: Oral

  • Pharmaceutical form:Tablet Route of administration: Oral

  • Pharmaceutical form:Tablet Route of administration: Oral

  • Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular

  • Pharmaceutical form:Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24

    RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Rheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24

    RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbances, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

    Time frame: Baseline, Weeks 4, 12 and 24

  2. Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12

    RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological wellbeing, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

    Time frame: Baseline, Weeks 4 and 12

  3. Hospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24

    HADS questionnaire measures the presence and severity of anxiety and depression in both hospital and community settings. The questionnaire comprised of 14 items divided into 2 subscales: 7 items for anxiety subscale (HADS-A) and 7 items for depression subscale (HADS-D). Each item was scored on a 0 to 3 rating scale. The anxiety and depression subscales each ranged from 0 to 21 (0-7: normal, 8-10: borderline abnormal and 11-21: abnormal), where higher scores indicated greater severity of anxiety/depression. The subscales were independent for each result of depression and anxiety.

    Time frame: Baseline, Weeks 4, 12 and 24

  4. Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24

    HADS questionnaire measures the presence and severity of anxiety and depression in both hospital and community settings. The questionnaire comprised of 14 items divided into 2 subscales: 7 items for anxiety subscale (HADS-A) and 7 items for depression subscale (HADS-D). Each item was scored on a 0 to 3 rating scale. The anxiety and depression subscales each ranged from 0 to 21 (0-7: normal, 8-10: borderline abnormal and 11-21: abnormal), where higher scores indicated greater severity of anxiety/depression. The subscales were independent for each result of depression and anxiety.

    Time frame: Baseline, Weeks 4, 12 and 24

  5. Multidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24

    MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a visual analog scale (VAS; in centimeters \[cm\]) ranged from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation.

    Time frame: Baseline, Weeks 4, 12 and 24

  6. Change From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24

    MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a VAS (in cm) ranging from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation.

    Time frame: Baseline, Weeks 4, 12 and 24

  7. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24

    FACIT-F was a 13-item questionnaire that assess fatigue in participants under chronic illness therapy. Participants scored each item on a 5-point Likert scale ranged from 0 to 4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The scores of each item were reversed during score calculations, so that higher score values indicated more favorable conditions. Total score was the sum of score from each item and resulted in a score range from 0 to 52, with higher score indicated better participant health status (lower level of fatigue).

    Time frame: Baseline, Weeks 4, 12 and 24

  8. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24

    FACIT-F was a 13-item questionnaire that assess fatigue in participants under chronic illness therapy. Participants scored each item on a 5-point Likert scale ranged from 0 to 4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The scores of each item were reversed during score calculations, so that higher score values indicated more favorable conditions. Total score was the sum of score from each item and resulted in a score range from 0 to 52, with higher score indicated better participant health status (lower level of fatigue).

    Time frame: Baseline, Weeks 4, 12 and 24

  9. Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24

    HAQ-DI was a participant-oriented questionnaire developed specifically to assess the extent of a RA participant's functional ability. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week (at each specified visit) rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, and ranged from 0 to 3, where 0 = no disability and 3 = completely disabled, higher score indicated more disability.

    Time frame: Baseline, Weeks 4, 12 and 24

  10. Change From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24

    HAQ-DI was a participant-oriented questionnaire developed specifically to assess the extent of a RA participant's functional ability. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week (at each specified visit) rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, and ranged from 0 to 3, where 0 = no disability and 3 = completely disabled, higher score indicated more disability.

    Time frame: Baseline, Weeks 4, 12 and 24

  11. Duration of Morning Stiffness at Baseline, Weeks 4, 12, and 24

    Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. At each specified time point, duration of morning stiffness was reported by the participant during the visit.

    Time frame: Baseline, Weeks 4, 12 and 24

  12. Change From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24

    Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. At each specified time point, duration of morning stiffness was reported by the participant during the visit.

    Time frame: Baseline, Weeks 4, 12 and 24

  13. International Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24

    IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in metabolic equivalent (MET)-minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity.

    Time frame: Baseline, Weeks 4, 12 and 24

  14. Change From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24

    IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in MET minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity.

    Time frame: Baseline, Weeks 4, 12 and 24

  15. Patient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24

    PtGA of disease activity was measured using a 100 millimeters (mm) horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

    Time frame: Baseline, Weeks 4, 12 and 24

  16. Change From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24

    PtGA of disease activity was measured using a 100 mm horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

    Time frame: Baseline, Weeks 4, 12 and 24

  17. Erythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24

    ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h).

    Time frame: Baseline, Weeks 4, 12 and 24

  18. Change From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

    ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in mm/h.

    Time frame: Baseline, Weeks 4, 12 and 24

  19. Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24

    DAS28-ESR was a composite score that included 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score less than or equal to (\<=) 3.2 indicated low disease activity (LDA), greater than (\>) 3.2 to \<=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

    Time frame: Baseline, Weeks 4, 12 and 24

  20. Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

    DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score \<= 3.2 indicated LDA, \> 3.2 to \<=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

    Time frame: Baseline, Weeks 4, 12 and 24

  21. Clinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24

    CDAI was a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment of disease (in cm). CDAI total score ranges from 0 to 76 with a lower score indicating less disease activity. A CDAI score of \<=2.8 represents clinical remission and a score of \<=10.0 represents LDA.

    Time frame: Baseline, Weeks 4, 12 and 24

  22. Change From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24

    CDAI was a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment of disease (in cm). CDAI total score ranges from 0 to 76 with a lower score indicating less disease activity. A CDAI score of \<=2.8 represents clinical remission and a score of \<=10.0 represents LDA.

    Time frame: Baseline, Weeks 4, 12 and 24

  23. Number of Swollen Joints at Baseline, Weeks 4, 12, and 24

    Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

    Time frame: Baseline, Weeks 4, 12 and 24

  24. Change From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24

    Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

    Time frame: Baseline, Weeks 4, 12 and 24

  25. Number of Tender Joints at Baseline, Weeks 4, 12, and 24

    Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

    Time frame: Baseline, Weeks 4, 12 and 24

  26. Change From Baseline in Number of Tender Joints at Weeks 4, 12, and 24

    Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

    Time frame: Baseline, Weeks 4, 12 and 24

  27. Number of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24

    DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable) marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score \<= 3.2 indicated LDA, \> 3.2 to \<=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

    Time frame: Weeks 12 and 24

  28. Number of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24

    CDAI was a composite index constructed to measure clinical remission in RA that does not included a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment (in cm). Total score ranged from 0 to 76 with a lower score indicated less disease activity. A CDAI score of \<=2.8 represents clinical remission and a score of \<=10.0 represents LDA.

    Time frame: Weeks 12 and 24

  29. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the study treatment. SAE: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that occurred in the time from the first injection of study drug up to 39.7 weeks.

    Time frame: Baseline up to end of study (up to 39.7 weeks)

07

Results

Posted Aug 10, 2020
Limitations and caveats
Secondary efficacy analyses was planned to be performed on the Per-protocol population (PPS), only when PPS represented less than 90 percent of the ITT population.

Participant flow

The study was conducted at 31 active centers in France. A total of 104 participants were screened between 05 March 2018 to 27 December 2018, of which 20 were screen failures. Screen failures were mainly due to inclusion criteria not met.

Participant flow — Overall Study
MilestoneSarilumab
Started84
Completed65
Not completed19
Withdrew: Major protocol deviation1
Withdrew: Treatment inefficacy5
Withdrew: Adverse event9
Withdrew: Consent withdrawal1
Withdrew: Other unspecified reason3

Outcome measures

PrimaryChange From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24
score on a scaleSarilumab
Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24-2.4 ± 2.3
SecondaryRheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbances, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Rheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24
score on a scaleSarilumab
Week 44.6 ± 2.1
Week 123.9 ± 2.3
Week 243.3 ± 2.5
SecondaryChange From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological wellbeing, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12
score on a scaleSarilumab
Week 4-1.2 ± 1.6
Week 12-1.8 ± 2.2
SecondaryHospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24

HADS questionnaire measures the presence and severity of anxiety and depression in both hospital and community settings. The questionnaire comprised of 14 items divided into 2 subscales: 7 items for anxiety subscale (HADS-A) and 7 items for depression subscale (HADS-D). Each item was scored on a 0 to 3 rating scale. The anxiety and depression subscales each ranged from 0 to 21 (0-7: normal, 8-10: borderline abnormal and 11-21: abnormal), where higher scores indicated greater severity of anxiety/depression. The subscales were independent for each result of depression and anxiety.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Hospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24
score on a scaleSarilumab
HADS-A: Baseline8.1 ± 4.3
HADS-A: Week 47.2 ± 4.3
HADS-A: Week 126.1 ± 3.7
HADS-A: Week 246.6 ± 3.9
HADS-D: Baseline7.0 ± 3.9
HADS-D: Week 46.6 ± 4.0
HADS-D: Week 125.7 ± 4.1
HADS-D: Week 245.5 ± 4.1
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24

HADS questionnaire measures the presence and severity of anxiety and depression in both hospital and community settings. The questionnaire comprised of 14 items divided into 2 subscales: 7 items for anxiety subscale (HADS-A) and 7 items for depression subscale (HADS-D). Each item was scored on a 0 to 3 rating scale. The anxiety and depression subscales each ranged from 0 to 21 (0-7: normal, 8-10: borderline abnormal and 11-21: abnormal), where higher scores indicated greater severity of anxiety/depression. The subscales were independent for each result of depression and anxiety.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24
score on a scaleSarilumab
HADS-A: Week 4-1.0 ± 2.4
HADS-A: Week 12-2.1 ± 3.3
HADS-A: Week 24-1.9 ± 3.2
HADS-D: Week 4-0.4 ± 2.5
HADS-D: Week 12-1.2 ± 4.1
HADS-D: Week 24-1.7 ± 3.7
SecondaryMultidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24

MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a visual analog scale (VAS; in centimeters \[cm\]) ranged from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · cm
Multidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24
cmSarilumab
Baseline88.4 ± 21.1
Week 489.6 ± 20.3
Week 1294.8 ± 13.6
Week 2490.9 ± 22.3
SecondaryChange From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24

MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a VAS (in cm) ranging from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · cm
Change From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24
cmSarilumab
Week 4-0.2 ± 24.2
Week 122.9 ± 17.7
Week 24-1.1 ± 23.4
SecondaryFunctional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24

FACIT-F was a 13-item questionnaire that assess fatigue in participants under chronic illness therapy. Participants scored each item on a 5-point Likert scale ranged from 0 to 4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The scores of each item were reversed during score calculations, so that higher score values indicated more favorable conditions. Total score was the sum of score from each item and resulted in a score range from 0 to 52, with higher score indicated better participant health status (lower level of fatigue).

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24
score on a scaleSarilumab
Baseline25.5 ± 10.3
Week 421.0 ± 10.5
Week 1218.8 ± 9.7
Week 2417.9 ± 11.4
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24

FACIT-F was a 13-item questionnaire that assess fatigue in participants under chronic illness therapy. Participants scored each item on a 5-point Likert scale ranged from 0 to 4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The scores of each item were reversed during score calculations, so that higher score values indicated more favorable conditions. Total score was the sum of score from each item and resulted in a score range from 0 to 52, with higher score indicated better participant health status (lower level of fatigue).

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24
score on a scaleSarilumab
Week 4-4.8 ± 8.0
Week 12-6.4 ± 9.1
Week 24-7.6 ± 10.8
SecondaryStanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24

HAQ-DI was a participant-oriented questionnaire developed specifically to assess the extent of a RA participant's functional ability. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week (at each specified visit) rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, and ranged from 0 to 3, where 0 = no disability and 3 = completely disabled, higher score indicated more disability.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24
score on a scaleSarilumab
Baseline1.3 ± 0.8
Week 41.1 ± 0.7
Week 120.8 ± 0.7
Week 240.8 ± 0.8
SecondaryChange From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24

HAQ-DI was a participant-oriented questionnaire developed specifically to assess the extent of a RA participant's functional ability. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week (at each specified visit) rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, and ranged from 0 to 3, where 0 = no disability and 3 = completely disabled, higher score indicated more disability.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24
score on a scaleSarilumab
Week 4-0.2 ± 0.5
Week 12-0.4 ± 0.6
Week 24-0.5 ± 0.8
SecondaryDuration of Morning Stiffness at Baseline, Weeks 4, 12, and 24

Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. At each specified time point, duration of morning stiffness was reported by the participant during the visit.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · minutes
Duration of Morning Stiffness at Baseline, Weeks 4, 12, and 24
minutesSarilumab
Baseline72.3 ± 75.0
Week 434.7 ± 43.9
Week 1228.9 ± 47.2
Week 2421.3 ± 37.5
SecondaryChange From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24

Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. At each specified time point, duration of morning stiffness was reported by the participant during the visit.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · minutes
Change From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24
minutesSarilumab
Week 4-39.9 ± 67.9
Week 12-47.9 ± 76.8
Week 24-52.8 ± 72.3
SecondaryInternational Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24

IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in metabolic equivalent (MET)-minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · MET minutes per week
International Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24
MET minutes per weekSarilumab
Baseline1759.9 ± 1185.0
Week 41881.1 ± 1203.9
Week 122061.0 ± 1266.9
Week 242089.5 ± 1476.4
SecondaryChange From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24

IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in MET minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · MET minutes per week
Change From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24
MET minutes per weekSarilumab
Week 4175.6 ± 1177.7
Week 12533.4 ± 1509.7
Week 24382.0 ± 1719.8
SecondaryPatient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24

PtGA of disease activity was measured using a 100 millimeters (mm) horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · mm
Patient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24
mmSarilumab
Baseline61.1 ± 22.4
Week 444.1 ± 25.6
Week 1236.6 ± 26.7
Week 2434.6 ± 25.6
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24

PtGA of disease activity was measured using a 100 mm horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24
mmSarilumab
Week 4-17.2 ± 24.2
Week 12-24.3 ± 31.8
Week 24-26.7 ± 29.6
SecondaryErythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24

ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h).

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · mm/h
Erythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24
mm/hSarilumab
Baseline28.8 ± 23.4
Week 410.5 ± 15.5
Week 129.2 ± 15.3
Week 248.4 ± 11.3
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in mm/h.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · mm/h
Change From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24
mm/hSarilumab
Week 4-18.1 ± 21.1
Week 12-19.5 ± 25.1
Week 24-22.0 ± 23.2
SecondaryDisease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24

DAS28-ESR was a composite score that included 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score less than or equal to (\<=) 3.2 indicated low disease activity (LDA), greater than (\>) 3.2 to \<=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24
score on a scaleSarilumab
Baseline5.0 ± 1.2
Week 43.1 ± 1.5
Week 122.6 ± 1.5
Week 242.3 ± 1.4
SecondaryChange From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score \<= 3.2 indicated LDA, \> 3.2 to \<=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24
score on a scaleSarilumab
Week 4-1.8 ± 1.1
Week 12-2.3 ± 1.6
Week 24-2.7 ± 1.5
SecondaryClinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment of disease (in cm). CDAI total score ranges from 0 to 76 with a lower score indicating less disease activity. A CDAI score of \<=2.8 represents clinical remission and a score of \<=10.0 represents LDA.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Clinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24
score on a scaleSarilumab
Baseline22.5 ± 11.2
Week 412.6 ± 9.8
Week 129.9 ± 10.4
Week 248.1 ± 7.8
SecondaryChange From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment of disease (in cm). CDAI total score ranges from 0 to 76 with a lower score indicating less disease activity. A CDAI score of \<=2.8 represents clinical remission and a score of \<=10.0 represents LDA.

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24
score on a scaleSarilumab
Week 4-9.8 ± 8.1
Week 12-12.2 ± 13.2
Week 24-14.6 ± 12.6
SecondaryNumber of Swollen Joints at Baseline, Weeks 4, 12, and 24

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · joints
Number of Swollen Joints at Baseline, Weeks 4, 12, and 24
jointsSarilumab
Baseline6.3 ± 5.1
Week 42.5 ± 3.2
Week 121.9 ± 3.6
Week 241.6 ± 2.8
SecondaryChange From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · joints
Change From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24
jointsSarilumab
Week 4-3.9 ± 4.3
Week 12-4.1 ± 5.1
Week 24-4.7 ± 5.2
SecondaryNumber of Tender Joints at Baseline, Weeks 4, 12, and 24

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · joints
Number of Tender Joints at Baseline, Weeks 4, 12, and 24
jointsSarilumab
Baseline7.3 ± 5.8
Week 44.7 ± 5.4
Week 123.5 ± 5.2
Week 242.5 ± 4.1
SecondaryChange From Baseline in Number of Tender Joints at Weeks 4, 12, and 24

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time frame:
Baseline, Weeks 4, 12 and 24
Reported as:
Mean · joints
Change From Baseline in Number of Tender Joints at Weeks 4, 12, and 24
jointsSarilumab
Week 4-2.5 ± 4.5
Week 12-3.7 ± 6.5
Week 24-4.8 ± 6.4
SecondaryNumber of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24

DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable) marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score \<= 3.2 indicated LDA, \> 3.2 to \<=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

Time frame:
Weeks 12 and 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24
ParticipantsSarilumab
LDA: Week 1212
LDA: Week 244
Remission: Week 1240
Remission: Week 2445
SecondaryNumber of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not included a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment (in cm). Total score ranged from 0 to 76 with a lower score indicated less disease activity. A CDAI score of \<=2.8 represents clinical remission and a score of \<=10.0 represents LDA.

Time frame:
Weeks 12 and 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24
ParticipantsSarilumab
LDA: Week 1229
LDA: Week 2429
Remission: Week 1218
Remission: Week 2420
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the study treatment. SAE: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that occurred in the time from the first injection of study drug up to 39.7 weeks.

Time frame:
Baseline up to end of study (up to 39.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsSarilumab
SAE10
TEAE76
AE leading to death0

Adverse events

Collected over All AEs were collected from the time of first injection of study drug up to 39.7 weeks regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarilumab0/84 (0%)10/84 (11.9%)54/84 (64.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSarilumab
NeutropeniaBlood and lymphatic system disorders1/84
Drug HypersensitivityImmune system disorders1/84
PneumoniaInfections and infestations1/84
Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders1/84
ArthritisMusculoskeletal and connective tissue disorders1/84
Back PainMusculoskeletal and connective tissue disorders1/84
Lumbar Spinal StenosisMusculoskeletal and connective tissue disorders1/84
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders1/84
PolyneuropathyNervous system disorders1/84
Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders1/84
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSarilumab
NeutropeniaBlood and lymphatic system disorders16/84
NauseaGastrointestinal disorders10/84
BronchitisInfections and infestations10/84
AstheniaGeneral disorders9/84
FatigueGeneral disorders9/84
NasopharyngitisInfections and infestations9/84
HeadacheNervous system disorders9/84
PruritusSkin and subcutaneous tissue disorders6/84
DiarrhoeaGastrointestinal disorders5/84
Injection Site ErythemaGeneral disorders5/84

Baseline characteristics

Analysis was performed on intent-to-treat (ITT) population which included participants who met all the eligibility criteria and received study treatment at least once.

Age, Continuous
Age, Continuous(years)Sarilumab
Mean59.1 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Sarilumab
Female63
Male21
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Sarilumab
Rheumatoid Arthritis Impact of Disease (RAID) - Baseline Total Score
Rheumatoid Arthritis Impact of Disease (RAID) - Baseline Total Score(score on a scale)Sarilumab
Mean5.8 ± 1.9
08

Study locations

33 sites
  • Investigational Site Number 250007
    Argenteuil, France
  • Investigational Site Number 250006
    Besancon, 25030, France
  • Investigational Site Number 250027
    Bobigny, 93000, France
  • Investigational Site Number 250016
    Bordeaux, 33076, France
  • Investigational Site Number 250014
    Caen, 14033, France
  • Investigational Site Number 250032
    CAHORS Cedex 9, 46005, France
  • Investigational Site Number 250019
    Cannes, 06414, France
  • Investigational Site Number 250013
    Cholet, 49325, France
  • Investigational Site Number 250002
    Clermont Ferrand, 63003, France
  • Investigational Site Number 250009
    Echirolles, 38434, France
  • Investigational Site Number 250005
    La Roche Sur Yon, 85025, France
  • Investigational Site Number 250024
    Le Mans Cedex 9, 72037, France
  • Investigational Site Number 250004
    Lille Cedex, 59037, France
  • Investigational Site Number 250012
    Limoges Cedex, 87000, France
  • Investigational Site Number 250021
    Lyon, 69495, France
  • Investigational Site Number 250018
    Montivilliers, France
  • Investigational Site Number 250029
    MONTPELLIER Cedex 5, 34295, France
  • Investigational Site Number 250025
    NANTES Cedex 1, 44035, France
  • Investigational Site Number 250026
    Nice cedex 1, 06001, France
  • Investigational Site Number 250020
    Paris Cedex 10, 75475, France
  • Investigational Site Number 250011
    PARIS Cedex 13, 75013, France
  • Investigational Site Number 250010
    Paris, 75012, France
  • Investigational Site Number 250015
    Paris, 75014, France
  • Investigational Site Number 250028
    Paris, 75015, France
  • Investigational Site Number 250033
    Paris, France
  • Investigational Site Number 250031
    Poitiers, 86021, France
  • Investigational Site Number 250023
    Pontoise, 95300, France
  • Investigational Site Number 250017
    RENNES Cedex, 35022, France
  • Investigational Site Number 250008
    Rouen, 76000, France
  • Investigational Site Number 250001
    St Etienne, 42055, France
  • Investigational Site Number 250034
    Strasbourg Cedex 2, 67098, France
  • Investigational Site Number 250022
    Toulouse, 31200, France
  • Investigational Site Number 250003
    Tours, 37000, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2019, 16 months.

Results were first posted in Aug 2020, 1 year after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 16 months is below that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2018
First posted
Feb 28, 2018
StartActual
Mar 5, 2018
Primary completionActual
Jul 31, 2019
CompletionActual
Jul 31, 2019
Results first posted
Aug 10, 2020
Last update
Apr 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03449758
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Mar 5, 2018
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019
Results posted
Aug 10, 2020
Last update
Apr 28, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion